CLEAR 1002-043
A randomized, double-blind, placebo-controlled study to assess the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant
- Stage
- klaar
- Medicine
- bempedoic acid
- Population
- ASCVD
- Phase
- III
- First Patient In
- 3 May 2017
- Last Patient In
- 14 August 2019
- Last Patient Last Visit
- 31 July 2022
National Lead
prof. dr. J. W. Jukema
Cardioloog
Study Director
dr. E. Ronner
Cardioloog
Office Contact
